LSX

ORYZON to Provide Corporate Progress Updates at Several Events in April

Retrieved on: 
Friday, April 5, 2024
Conference, Biotechnology, Genomics, LSX, BST, Pharma, Cryptocurrency

Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.

Key Points: 
  • Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.
  • The company will hold one-on-one meetings with pharmaceutical companies.
  • Oryzon will take part in the keynote plenary panel entitled “The inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future” on April 29 at 16:20 BST.
  • Click on the link for more info about the LSX World Congress 2024

Calliditas Therapeutics to Attend Conferences in April

Retrieved on: 
Tuesday, April 9, 2024
Congress, Conference, CALT, Future, Sustainability, LSX, Inflation, Pharma, Person, Pharmaceutical industry

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
    Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024.
  • Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
  • World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA.
  • Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

Calliditas Therapeutics to Attend Conferences in April

Retrieved on: 
Tuesday, April 9, 2024
Congress, Conference, CALT, Future, Sustainability, LSX, Inflation, Pharma, Person, Pharmaceutical industry

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
    Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024.
  • Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
  • World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA.
  • Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024

Retrieved on: 
Thursday, March 28, 2024
Health, Surgery, General Health, Research, Science, Pharmaceutical, Biotechnology, Path, LSX, Congress, Business development, Commercialization

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio€quity Europe (12-14 May).

Key Points: 
  • VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio€quity Europe (12-14 May).
  • The LSX World Congress is the leading partnering, strategy and investment event in Europe, with 1:1 partnering at its core.
  • Bio€quity Europe is a key biopartnering event for the biotech industry in Europe, organised by BioCentury.
  • If you are interested in meeting with the VarmX Team at either of these upcoming events, or to get further information, please contact: [email protected] .

Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

Retrieved on: 
Thursday, November 16, 2023
Patient, Culture, ELAS, LSX, Growth, Hypoparathyroidism, Pharmaceutical industry

LYON, France and CAMBRIDGE, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, has been awarded ‘Biotech Company of the Year 2023’ at the annual LSX, European Lifestars Awards Ceremony, held on November 13th in London, U.K.

Key Points: 
  • LYON, France and CAMBRIDGE, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, has been awarded ‘Biotech Company of the Year 2023’ at the annual LSX, European Lifestars Awards Ceremony, held on November 13th in London, U.K.
  • The European Lifestars Awards (ELAs) are an annual event that acknowledges and celebrates the significant achievements within the life sciences sector across Europe.
  • These awards recognize the innovation and ground-breaking achievements of the life sciences industry's most distinguished executive leaders, investors, partners, and dealmakers for their outstanding contributions to the advancement of the industry.
  • Together, we've cultivated a culture of excellence and commitment towards patients, advancing our clinical pipeline of therapeutic peptides for rare endocrine diseases.

Lisata Therapeutics Announces Participation in Upcoming Conferences in November

Retrieved on: 
Thursday, November 9, 2023
LSX, Doctor of Philosophy, Conference, Therapy

Management will also participate in one-on-one meetings with investors that day.

Key Points: 
  • Management will also participate in one-on-one meetings with investors that day.
  • Management will participate in one-on-one meetings at the Jefferies London Healthcare Conference.
  • Dr. Mazzo will deliver a virtual presentation on Wednesday, November 29, 2023 at 6:00pm PT / 9:00pm ET.
  • This is an invitation only event that consists of institutional, industrial, and high net worth investors in the Asia Pacific.

Lazzara Yachts Announces LSX 67 Limited Edition US Premiere, New US Office

Retrieved on: 
Tuesday, October 10, 2023
LSX, Limited Edition, Stainless steel, Carbon, Adventure, LMC, VIP, Water, Interior design, Shipbuilding, Broker

FORT LAUDERDALE, Fla., Oct. 10, 2023 /PRNewswire-PRWeb/ -- "We destroy standards to create new adventures," says David Galante, Lazzara Yachts Executive Vice President, with pride. Breaking standards was required to create the Limited Edition extension of Lazzara Yachts' award-winning LSX 67 model. The LSX 67 Limited Edition has a striking midnight blue exterior and features a long list of fan-favorite upgrades, including a revolutionized master, seamless wood interior, and spacious walkways.

Key Points: 
  • Breaking standards was required to create the Limited Edition extension of Lazzara Yachts' award-winning LSX 67 model.
  • Breaking standards was required to create the Limited Edition extension of Lazzara Yachts' award-winning LSX 67 model.
  • The LSX 67 Limited Edition has a striking midnight blue exterior and features a long list of fan-favorite upgrades, including a revolutionized master, seamless wood interior, and spacious walkways.
  • View the LSX 67 Limited Edition video tour on Lazzara Yachts YouTube channel, click here .

Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston

Retrieved on: 
Monday, September 11, 2023
LSX, IBN, Conference, Nightclub

JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., announced today that CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and 12) and LSX USA Congress 2023 in Boston this Wednesday and Thursday (Sept. 13 and 14).

Key Points: 
  • JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., announced today that CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and 12) and LSX USA Congress 2023 in Boston this Wednesday and Thursday (Sept. 13 and 14).
  • Investors and potential business partners interested in meeting with Mr. Reichman and Mr. Germain are invited to contact Scinai investor relations at [email protected] to request a meeting.
  • In addition, members of Scinai’s senior leadership team will be attending the CPHI Barcelona conference in October.
  • Events that Scinai plans to attend are listed on Scinai’s new website at https://www.scinai.com/events .

DepYmed to Meet with Investors at the LSX World Congress USA in Boston on September 13-14, 2023

Retrieved on: 
Friday, September 8, 2023
PTP, Enzyme, Congress, Rare, Family, LSX, Pharmaceutical industry, Financial adviser

FARMINGDALE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.

Key Points: 
  • FARMINGDALE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.
  • Today the Company announces that management will be meeting with investors at the LSX World Congress USA conference in Boston from September 13-14, 2023.
  • Interested investors can register free of charge for the conference here and arrange meetings with the Company.
  • In addition, meetings can be arranged via email at [email protected] .

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

Retrieved on: 
Tuesday, September 5, 2023
Congress, Therapy, Conference, LSX, Doctor of Philosophy, Pharmaceutical industry, Airline

BASKING RIDGE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, Chief Executive Officer of Lisata, will present at two upcoming conferences in September.

Key Points: 
  • BASKING RIDGE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, Chief Executive Officer of Lisata, will present at two upcoming conferences in September.
  • Details of the events are as follows:
    September 11-13 | New York City, NY
    Dr. Mazzo’s presentation will be available on-demand on September 11, 2023, at 7:00 a.m. Eastern Time.
  • Management will also participate in one-on-one meetings with investors on September 11th.
  • Dr. Mazzo will deliver a live presentation on Thursday, September 14, 2023, at 11:00 a.m. Eastern Time.